Tech Company Financing Transactions
EverImmune Funding Round
On 9/19/2023, EverImmune raised $3.7 million in financing from Bpifrance.
Transaction Overview
Company Name
Announced On
9/19/2023
Transaction Type
Venture Equity
Amount
$3,740,000
Round
Undisclosed
Investors
Bpifrance (Lead Investor)
Proceeds Purpose
The company will be able to conduct a phase I/II clinical trial for its drug candidate Oncobax® AK in patients undergoing immunotherapy. The funding will be used to recruit 71 trial patients with Non-Small Cell Lung Cancer (NSCLC) or Renal Cell Cancer (RCC). EverImmune will investigate whether Oncobax AK improves the effectiveness of the patients' immunotherapy treatment. The clinical trial will be conducted in 15 hospitals throughout France and Belgium, including Gustave Roussy, the leading cancer center that spun-off everImmune.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
39 Rue Camille Desmoulins
Villejuif, 94800
FR
Villejuif, 94800
FR
Phone
Undisclosed
Website
Email Address
Overview
EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology. It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean-Luc Marsat
Co-Founder
Romain Daillère
Co-Founder
Guido Kroemer
Browse more venture capital transactions:
Prev: 9/19/2023: Electron venture capital transaction
Next: 9/19/2023: Paxton venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC transactions reported here are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs